| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Eppley Institute for Cancer Research, University of Nebraska College of Medicine, Omaha, Nebraska 68105
The growth of four tumorigenic cell lines was inhibited from 70 to 89% by adenosine 3', 5'-cyclic monophosphate (0.3 mM) whereas a nonmalignant cell line (WI-38) was affected only slightly (13%). Adenosine 2',3'-cyclic monophosphate (0.3 mM) was less active, inhibiting the tumorigenic cell lines from 23 to 56%.
The other cyclic purine nucleotides investigated (guanosine 3',5'-cyclic monophosphate and quanosine 2',3'-cyclic monophosphate) did not show selectivity; they inhibited the tumorigenic strains and the WI-38 cell line.
The 3',5'-cyclic pyrimidine nucleotides, with the exception of thymidine 3',5'-cyclic monophosphate, did not significantly inhibit any of the cell lines. Thymidine 3',5'-cyclic monophosphate produced inhibition of only strain L.
1 This research was supported by a Research Grant P-384C from the American Cancer Society.
2 Predoctoral trainee, USPHS Traineeship 2-TO1-HD-18.
Received 5/ 7/69. Accepted 7/16/69.
This article has been cited by other articles:
![]() |
Y. S. Cho-Chung and P. M. Gullino In vivo Inhibition of Growth of Two Hormone-Dependent Mammary Tumors by Dibutyryl Cyclic AMP Science, January 11, 1974; 183(4120): 87 - 88. [Abstract] [PDF] |
||||
![]() |
W. L. Ryan and M. A. Durick Adenosine 3',5'-Monophosphate and N6-2'-O-Dibutyryl-Adenosine 3',5'-Monophosphate Transport in Cells Science, September 15, 1972; 177(4053): 1002 - 1003. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |